Status:
ENROLLING_BY_INVITATION
Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer
Lead Sponsor:
Comprehensive Cancer Centre The Netherlands
Collaborating Sponsors:
University of Twente
Dutch Breast Cancer Association
Conditions:
Breast Cancer
Breast Cancer Female
Eligibility:
FEMALE
40+ years
Brief Summary
Surveillance and aftercare for curatively treated primary breast cancer patients is currently mostly 'one-size-fits-all', but can be personalized based on patients' risk of recurrence (depending on pa...
Detailed Description
1. Treatment of subjects: personalized follow-up Personalized Surveillance Plan (PSP): Around the first surveillance mammogram (i.e. one year after end of treatment), the personalized surveillance pla...
Eligibility Criteria
Inclusion
- female,
- aged 40 years or older (because of higher risk on recurrence),
- facing the decision for the organization of post-treatment surveillance and aftercare,
- being curatively treated including breast surgery, for invasive non-metastasized breast cancer
- able to understand the Dutch language in speech and writing.
Exclusion
- bilateral breast cancers,
- BRCA1/2 or CHEK2 carriers,
- having an indication for MRI
- participation in another study that requires fixed scheduled follow-up consultations and/or imaging.
Key Trial Info
Start Date :
March 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 6 2027
Estimated Enrollment :
1040 Patients enrolled
Trial Details
Trial ID
NCT05975437
Start Date
March 6 2023
End Date
March 6 2027
Last Update
August 3 2023
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Gelre Ziekenhuizen
Apeldoorn, Gelderland, Netherlands
2
Rijnstate
Arnhem, Gelderland, Netherlands
3
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, North Brabant, Netherlands
4
Bernhoven Ziekenhuis
Uden, North Brabant, Netherlands